Phase II study of Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy for maintenance of Patients With Neovascular Maculopathy

Phase II study of Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy for maintenance of Patients With Neovascular Maculopathy - Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy(Phase II)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006372

Enrollment

120

Registered

2011-09-20

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular Maculopathy

Interventions

According HLA typing, patients with A*0201 will be treated with vaccine therapy in addition ot Rabinismab (Lucentis) therapy According HLA typing, patients with A*2402 will be treated with vaccine the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Neovascular Maculopathy including Age Related Macular Degeneration. 2.Frequent Rabinismab (Lucentis) injection will be necesarry

Exclusion criteria

Exclusion criteria: Pregnancy(woman of childbearing potential:Refusal or inability to use effective means of contraception) Breast feeding Active or uncontrolled infection Unhealed external wound Concurrent treatment with steroids or immunosuppressing agent Uncontrolled brain and/or intraspinal lesion(s) Decision of unsuitableness by principal investigator or physician-in-charge.

Design outcomes

Primary

Measure	Time frame
Efficacy To reduce the intervention of Rabinismab(Lucentis) intra vitreous injection using with anti-VEGFR vaccine. (2years)	—

Countries

Japan

Contacts

Public ContactMotokazu Tsujikawa

Osaka University Medical School Ophthalmology

moto@ophthal.med.osaka-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026